Advertisement
The conference call will be accessible via Telik's website athttp://www.telik.com or by telephone at 800-398-9398 or 612-332-0530. Anarchive of the conference call will be available on the Telik website or bytelephone at 800-475-6701 or 320-365-3844, access code 910785. The archivewill be available from approximately 6:30 p.m. Eastern time on February 27through March 12, 2008.
Advertisement
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused ondiscovering, developing and commercializing novel small molecule drugs totreat serious diseases. The company's most advanced drug developmentcandidates are TELCYTA(R), a tumor-activated small molecule product candidatein clinical development for the treatment of advanced ovarian cancer andnon-small cell lung cancer; and TELINTRA(R), which is in clinical developmentfor the treatment of myelodysplastic syndrome. Telik's product candidates werediscovered using its proprietary drug discovery technology, TRAP(TM), whichenables the rapid and efficient discovery of small molecule drug candidates.
SOURCE Telik, Inc.
